KDR and hepatocellular carcinoma: Multitargeted TKIs such as sunitinib, regorafenib, and sorafenib—originally developed and validated in renal cell carcinoma, hepatocellular carcinoma, and mCRC—exert antitumor effects primarily via inhibition of VEGFR, PDGFR, RAF, and KIT-related signaling pathways.